Vincerx Pharma IncNASDAQ:VINC
- LAST PRICE1.3100
- TODAY'S CHANGE (%)-0.1400 (-9.6552%)
- Bid / Lots1.3300/ 50
- Ask / Lots1.3500/ 1
- Open / Previous Close1.4638 / 1.4500
- Day Range
- 52 Week Range
- Volume88,786
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VINC |
|---|---|---|
| 10:06 ET | 200 | 1.4638 |
| 10:09 ET | 100 | 1.48 |
| 10:22 ET | 100 | 1.4627 |
| 10:24 ET | 100 | 1.49 |
| 10:36 ET | 1000 | 1.49 |
| 10:42 ET | 400 | 1.48 |
| 10:51 ET | 10871 | 1.46 |
| 11:12 ET | 1300 | 1.46 |
| 11:16 ET | 400 | 1.46 |
| 11:18 ET | 1600 | 1.46 |
| 11:43 ET | 15191 | 1.455 |
| 11:45 ET | 400 | 1.445 |
| 12:08 ET | 228 | 1.45 |
| 12:26 ET | 1000 | 1.45 |
| 12:48 ET | 100 | 1.4003 |
| 12:50 ET | 2600 | 1.4001 |
| 01:00 ET | 738 | 1.4117 |
| 01:02 ET | 15272 | 1.4 |
| 01:04 ET | 7000 | 1.42 |
| 01:31 ET | 640 | 1.3641 |
| 01:42 ET | 100 | 1.4 |
| 01:45 ET | 200 | 1.36 |
| 01:56 ET | 226 | 1.3782 |
| 02:14 ET | 1400 | 1.37 |
| 02:30 ET | 2221 | 1.365 |
| 02:32 ET | 1000 | 1.365 |
| 02:36 ET | 1900 | 1.33 |
| 02:38 ET | 400 | 1.36 |
| 02:39 ET | 500 | 1.3341 |
| 02:54 ET | 500 | 1.3407 |
| 03:03 ET | 334 | 1.32 |
| 03:06 ET | 100 | 1.3101 |
| 03:08 ET | 1078 | 1.3106 |
| 03:10 ET | 225 | 1.33 |
| 03:17 ET | 1780 | 1.3125 |
| 03:24 ET | 495 | 1.3001 |
| 03:26 ET | 3814 | 1.33 |
| 03:28 ET | 300 | 1.3366 |
| 03:53 ET | 7780 | 1.32 |
| 03:57 ET | 400 | 1.32 |
| 04:00 ET | 970 | 1.31 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vincerx Pharma Inc | 27.8M | -0.5x | --- |
Aprea Therapeutics Inc | 27.8M | -0.1x | --- |
Addex Therapeutics Ltd | 25.9M | 0.0x | --- |
Goldenwell Biotech Inc | 28.3M | -286.4x | --- |
Regulus Therapeutics Inc | 27.1M | -0.8x | --- |
Edesa Biotech Inc | 28.6M | -1.2x | --- |
Company Information
Vincerx Pharma, Inc. is a clinical-stage life sciences company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s small molecule drug program includes VIP152, which is a selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. Its SMDC platform targets advanced solid tumors with optimized camptothecin, a potent cytotoxin (warhead, payload or toxophore).
Contact Information
- Headquarters
- 260 Sheridan Avenue, Suite 400PALO ALTO, CA, United States 94306
- Phone
- 650-800-6676
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Ahmed Hamdy
- President, Chief Operating Officer, Director
- Raquel Izumi
- Chief Financial Officer
- Alexander Seelenberger
- Chief Technology Officer
- Xiaoming Zhang
- General Counsel, Chief Legal Officer
- Tom Thomas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $27.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 21.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.77 |
Book Value | $4.76 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
